Last updated 2026-07-30
TL;DR
There's no established lethal or toxic dose of CJC-1295 in humans because it has never gone through controlled human trials at scale. Risk comes mainly from unregulated sourcing, DAC-related prolonged action, and additive effects when stacked with ipamorelin or other secretagogues, not from a known single-dose overdose threshold.
Is there a known lethal or toxic dose of CJC-1295 in humans?
No. There is no published human LD50, no FDA-reviewed maximum tolerated dose, and no clinical toxicity threshold for CJC-1295 in any peer-reviewed human trial. That's not a reassuring gap, it's an evidence gap. The compound has been studied in a small number of formal trials, most notably a 2006 Journal of Clinical Endocrinology & Metabolism study of CJC-1295 (with the DAC, drug affinity complex, formulation) in healthy adults, which tested single doses up to 60 micrograms per kilogram and repeated doses up to 30 micrograms per kilogram twice weekly [1]. That study reported sustained increases in GH and IGF-1 with dose-dependent effects, and described the compound as generally well tolerated at those doses, but it was not designed or powered to find a toxicity ceiling [1]. Outside that trial and a handful of related pharmacokinetic papers, CJC-1295 has not been through the kind of Phase II/III toxicology program that establishes a real overdose threshold the way we have for, say, insulin or acetaminophen. Anyone telling you a specific 'overdose dose' in milligrams is guessing, usually based on forum extrapolation from bodybuilding use, not controlled data. That distinction matters more here than almost anywhere else in the GH-secretagogue space. What we do know: CJC-1295 is not FDA-approved for any indication, human or otherwise [2]. It is sold as a research chemical, which means it hasn't gone through the safety and manufacturing review that would normally generate the toxicity data patients rely on for approved drugs.
What actually happens if you take too much CJC-1295?
Based on the pharmacology of growth-hormone-releasing hormone (GHRH) analogues and the adverse events reported in the limited human trial data, an acute overdose would most plausibly cause an exaggerated version of CJC-1295's known effects, not a novel toxic syndrome. Expect the volume, not a new disease. The 2006 trial and related GHRH literature describe injection site reactions (redness, itching, swelling), flushing, and headache as the most common adverse events at studied doses [1]. A GH-releasing peptide pushed past its intended range would be expected to intensify GH and prolactin pulses, which can produce more pronounced flushing, transient hypotension-related lightheadedness, water retention, joint or nerve-compression symptoms (carpal-tunnel-like tingling), and headache from intracranial pressure changes, effects that mirror what's seen in supraphysiologic GH states more broadly, including acromegaly literature on chronically elevated GH/IGF-1 [3]. Blood sugar is the other lever. GH antagonizes insulin action, and the same 2006 study noted small increases in fasting glucose at higher repeated doses [1]. A large acute dose, or repeated high dosing stacked with ipamorelin, could plausibly worsen insulin resistance over days to weeks rather than causing an acute glucose crisis. Nobody has published data confirming this at forum-reported human doses; this is a mechanistic inference, not an observed clinical outcome. There is no antidote for a GHRH analogue. Management of a suspected overdose is supportive: monitoring, symptomatic treatment, and time, since CJC-1295 without DAC has a short elimination half-life (roughly 30 minutes based on early GHRH analogue pharmacokinetics) while the DAC version is designed to persist for days [4].
Does the DAC version change the overdose risk?
| Approximate half-life | ~30 minutes [4] | ~6-8 days [1] | |
|---|---|---|---|
| GH pulse pattern | Mimics natural pulsatile GH release | Sustained, less pulsatile elevation | |
| Overdose consequence window | Hours | Days to over a week | |
| Dosing frequency in studied protocol | Not applicable (short-acting analogues typically dosed daily in related research) | Twice weekly in the 2006 trial [1] | If you're trying to understand how this plays out over weeks of use rather than a single dose, the CJC-1295 results timeline covers the expected onset curve, which is a useful reference point for noticing if something is off. |
Yes, meaningfully. CJC-1295 with DAC binds to serum albumin, which extends its half-life to roughly 6 to 8 days based on the pharmacokinetic modeling in the original trial, compared to a non-DAC (also called 'CJC-1295 without DAC' or sometimes mislabeled 'Mod GRF 1-29') half-life measured in minutes [1] [4]. That difference changes the shape of an overdose risk, more than its severity. A no-DAC dosing error is a bad day: the peptide clears fast, and any excess GH pulse resolves in hours. A DAC dosing error is a bad week or more: because the drug affinity complex keeps releasing active peptide from albumin over days, an accidental double dose (or repeated over-dosing before you realize a mistake) compounds. You can't 'undo' an injection once it's bound to albumin. This is the single biggest reason to treat DAC dosing errors more seriously than no-DAC ones, and why source-labeling confusion between the two products is a genuine safety problem, more than a technical detail. | Feature | CJC-1295 (no DAC) | CJC-1295 with DAC |
Can CJC-1295 cause organ damage or long-term toxicity?
There's no published human data showing organ damage from CJC-1295 at studied doses, but the theoretical concern is real and comes from what we know about chronically elevated GH and IGF-1, not from CJC-1295-specific toxicology. Acromegaly, the disease of chronic GH excess (usually from a pituitary tumor), is well documented in endocrinology literature and gives us the long-term roadmap of what sustained supraphysiologic GH does: cardiac hypertrophy, hypertension, joint disease, insulin resistance progressing toward diabetes, and soft tissue overgrowth [3]. That's the disease model. CJC-1295, especially the DAC version used chronically at doses well above studied protocols, could theoretically push someone toward a milder version of that picture over months to years. Nobody has run a multi-year controlled trial to confirm this happens at typical unsupervised-use doses, so treat it as a plausible risk grounded in adjacent disease biology, not a proven outcome. The more immediate, better-documented long-term concern is fluid retention and glucose handling. The original CJC-1295 trial reported dose-related increases in IGF-1 that persisted for the full study duration, alongside the glucose changes mentioned earlier [1]. If you're using this long-term, periodic fasting glucose and IGF-1 lab checks are a reasonable, low-cost way to catch a trend before it becomes a problem, and this is exactly the kind of monitoring that separates a considered protocol from forum-style dosing.
What are the warning signs of a CJC-1295 reaction or overdose?
Watch for a cluster, not a single symptom. Isolated mild flushing or a little injection-site redness is common and reported even at standard studied doses [1]. What should prompt you to stop and seek medical attention is a combination or an escalating pattern. Signs worth taking seriously: persistent or worsening headache (especially with visual changes, which can signal intracranial pressure changes), chest tightness or a racing heart, significant swelling in the hands, feet, or face, fainting or near-fainting, and any signs of a severe allergic reaction (hives, throat swelling, difficulty breathing). That last category is a true emergency regardless of the drug involved. Because the DAC version stays active for days, a reaction from it won't necessarily resolve quickly just because you stop dosing. If you experience a concerning symptom after a DAC dose, know that the exposure is ongoing, not a single bolus that's already cleared, and factor that into how urgently you seek care. There is no formal, published symptom checklist specific to CJC-1295 overdose because there's no clinical trial data at overdose-level doses. The guidance above is extrapolated from GHRH pharmacology and general supraphysiologic GH effects [1] [3], and from that gap alone you should take any unusual reaction seriously rather than assuming it's 'normal peptide stuff.'
What should you do if you think you've overdosed on CJC-1295?
Stop dosing immediately and contact your prescribing clinician or, in the US, poison control at 1-800-222-1222, a real, staffed line that handles exactly this kind of unregulated-substance exposure question and can triage severity over the phone. If symptoms are severe (chest pain, difficulty breathing, fainting, signs of anaphylaxis), go to an emergency department or call 911, don't wait for a callback. Bring the vial, packaging, or any documentation of the product to poison control or the ER if you can. Because CJC-1295 is not FDA-regulated, dose accuracy and purity vary by source, and knowing exactly what was injected (concentration, whether it was DAC or no-DAC, what else was in the vial) meaningfully changes how a clinician should think about your case [2]. Write down the timeline: when you dosed, how much you believe you took, what else you've taken recently (especially other GH secretagogues like ipamorelin, or insulin, which interacts with GH's glucose effects). This kind of note is genuinely useful to whoever treats you and costs you nothing to prepare in the moment. There is no reversal agent to request. Supportive care, meaning symptom management and monitoring, is what you'll get, and for the no-DAC version that supportive window is short because the drug clears in about half an hour [4]. For DAC, plan on the exposure mattering for days.
Is combining CJC-1295 with ipamorelin more dangerous than either alone?
The rationale for pairing them is mechanistic, not an established safety-tested combination. CJC-1295 is a GHRH analogue that raises the baseline GH signal; ipamorelin is a ghrelin-receptor agonist (a GH secretagogue in a different class) that triggers a separate GH pulse. Combining a GHRH analogue with a ghrelin mimetic to get a larger or more reliable GH pulse than either alone is a real, published pharmacological concept in growth hormone secretagogue research generally [5], but that's a mechanism-level rationale, not a clinical trial showing this specific combination is safe at the doses commonly used outside medical supervision. In terms of overdose risk specifically: stacking two GH secretagogues plausibly increases the size of each GH pulse rather than creating a new toxicity, since they converge on the same downstream hormone. That means the symptom profile of an overdose on the combination should look like an amplified version of what either drug causes alone (flushing, water retention, glucose effects, headache), not a distinct toxic syndrome. But 'plausibly' is doing real work in that sentence. Nobody has published controlled dose-escalation safety data on the CJC-1295-plus-ipamorelin combination specifically, so anyone claiming a proven safe combined ceiling is not citing real evidence. If you're weighing whether the combination is worth the added variables, the honest starting points are the CJC-1295 pros and cons analysis and CJC-1295 reviews, both of which separate documented effects from anecdote rather than assuming the pairing is automatically better.
How does sourcing quality affect overdose and toxicity risk?
This is arguably the biggest real-world overdose risk factor, bigger than the peptide's inherent pharmacology. CJC-1295 sold outside a licensed pharmacy supply chain is not FDA-inspected for purity, concentration accuracy, or sterility [2]. A vial labeled '2mg' with actual content anywhere from 50% to 150% of that label turns a 'standard dose' into an accidental overdose or underdose without the user ever changing their behavior. Contamination is a separate risk from concentration error. Improperly compounded or improperly stored peptide solutions can carry bacterial contamination, and an injected contaminant doesn't present as 'CJC-1295 toxicity,' it presents as an injection-site infection or a systemic infection that gets misattributed to the peptide itself. This is a supply chain problem, not a drug pharmacology problem, but it's the one most within your control. The practical fix is provider-reviewed sourcing: a route where a clinician reviews your history and the product is fulfilled through a real, licensed pharmacy rather than an unregulated research-chemical vendor. CJC-1295 Co is built around exactly that distinction, pointing readers toward provider-reviewed access with a named, licensed pharmacy partner completing the fulfillment, rather than a gray-market vial with no chain of custody. That doesn't eliminate the drug's mechanistic unknowns, but it removes the concentration-error and contamination variables that account for a large share of real-world 'overdose' reports.
Who should not use CJC-1295 at all, given these risks?
Several groups carry categorically higher risk and the mechanistic reasoning is straightforward even without CJC-1295-specific trial data. Anyone with a history of cancer, especially hormone-sensitive or GH/IGF-1-sensitive tumors, should avoid GH secretagogues; elevated IGF-1 is a growth signal, and the established acromegaly and IGF-1 literature links sustained elevation to tumor-growth concerns [3]. People with poorly controlled diabetes or significant insulin resistance face amplified risk because GH's glucose-raising effect stacks on top of an already-compromised system [1] [3]. Pregnant or breastfeeding people should avoid it outright, since there's no safety data in pregnancy at all, let alone overdose data. Anyone with untreated pituitary disease, uncontrolled hypertension, or active cardiac disease should treat CJC-1295 as higher-risk given GH's known cardiovascular effects in acromegaly patients [3]. And functionally, anyone who can't verify what's actually in their vial, meaning no provider oversight and no pharmacy-grade sourcing, is taking on a real, avoidable risk layer regardless of their baseline health. If you're still deciding whether the tradeoffs make sense for you at all, is CJC-1295 worth it and the CJC-1295 before and after page both walk through realistic outcome expectations against these same risk categories.
Frequently asked questions
What is the maximum safe dose of CJC-1295?
There's no FDA-established maximum safe dose because CJC-1295 isn't an approved drug. The 2006 clinical trial tested single doses up to 60 mcg/kg and repeated dosing up to 30 mcg/kg twice weekly with general tolerability, but that's a studied range in a small trial, not a certified safety ceiling for wider use [1].
Can CJC-1295 kill you?
No published case documents a CJC-1295 death, and no LD50 exists in humans. The realistic danger isn't a single fatal dose, it's cumulative risk from unregulated sourcing (contamination, concentration errors) and from underlying conditions like active cancer or uncontrolled diabetes that GH elevation can worsen over time [2][3].
What's the difference between CJC-1295 with DAC and without DAC for safety?
DAC extends the half-life to roughly 6 to 8 days by binding albumin, versus about 30 minutes without it [1][4]. That means a dosing mistake with DAC stays active in your system far longer, so errors compound instead of clearing within hours as they would with no-DAC CJC-1295.
What are the most common side effects at normal doses?
The 2006 clinical trial reported injection site reactions, flushing, and headache as the most frequent adverse events at studied doses [1]. These are generally mild and described as tolerable in that trial, but they're the same symptoms that would intensify in an overdose scenario, just at greater severity or duration.
Does CJC-1295 raise blood sugar?
The original trial found small, dose-related increases in fasting glucose with repeated higher-dose administration [1]. This tracks with GH's known role as an insulin antagonist, seen more dramatically in acromegaly patients with chronic GH excess [3]. Anyone with insulin resistance or diabetes should treat this as a real, not theoretical, monitoring point.
Is it dangerous to combine CJC-1295 with ipamorelin?
The two work through different receptors (GHRH receptor versus ghrelin receptor) and combining them is meant to produce a larger GH pulse than either alone, a mechanism with real pharmacological basis [6]. But no controlled human safety trial has tested this specific combination at commonly used doses, so treat any overdose risk as an amplified version of each drug's individual effects, not a proven safe combination.
What should I do if I accidentally injected too much CJC-1295?
Stop dosing, call US Poison Control at 1-800-222-1222 for real-time guidance, and seek emergency care immediately if you have chest pain, trouble breathing, fainting, or signs of severe allergic reaction [5]. Bring the vial or packaging with you. There's no antidote, so treatment is supportive and monitoring-based.
Is CJC-1295 FDA approved, and does that affect toxicity risk?
No. CJC-1295 has no FDA approval for any use and is not reviewed for manufacturing quality or dosing safety the way approved drugs are [2]. That regulatory gap is a major reason concentration errors and contamination, not the peptide's pharmacology alone, drive most real-world adverse reports.
Can long-term CJC-1295 use cause organ damage?
No CJC-1295-specific long-term human toxicity study exists. The theoretical concern is modeled on acromegaly, the disease of chronic GH excess, which is linked to cardiac hypertrophy, hypertension, and joint disease over years [3]. Periodic IGF-1 and glucose monitoring is a reasonable precaution for anyone using it long-term without that risk being proven inevitable.
Who should avoid CJC-1295 entirely because of toxicity risk?
People with a history of hormone-sensitive or GH-sensitive cancers, poorly controlled diabetes, untreated pituitary disease, significant cardiac disease, or pregnancy should avoid it. Elevated GH and IGF-1 are growth signals with documented risk in these groups from the broader acromegaly and oncology literature, even without CJC-1295-specific overdose data [3].
How fast does CJC-1295 leave your system if something goes wrong?
No-DAC CJC-1295 has an estimated half-life around 30 minutes, so it clears within hours [4]. CJC-1295 with DAC has a half-life of roughly 6 to 8 days because it binds serum albumin, meaning any adverse reaction or dosing error stays biologically active far longer [1].
Does poor sourcing increase overdose risk even at a 'normal' dose?
Yes, significantly. Unregulated peptide vials aren't FDA-inspected for accurate concentration, so a labeled dose can actually deliver well above or below what's stated [2]. This is why provider-reviewed access through a licensed pharmacy, the model CJC-1295 Co points readers toward, removes a major real-world risk variable that has nothing to do with the drug's inherent pharmacology.
Sources
- Teichman SL et al., Journal of Clinical Endocrinology & Metabolism, 2006: Dose ranges, GH/IGF-1 effects, adverse events, and pharmacokinetics of CJC-1295 with DAC in a controlled human trial
- U.S. Food and Drug Administration, FDA-approved drug search (Drugs@FDA): CJC-1295 has no FDA approval for any human indication
- National Institute of Diabetes and Digestive and Kidney Diseases, Acromegaly overview: Chronic GH excess (acromegaly) is linked to cardiac hypertrophy, hypertension, glucose intolerance, and joint disease
- Ionescu M, Frohman LA, Journal of Clinical Endocrinology & Metabolism, 2006: Half-life differences between short-acting GHRH analogues and DAC-modified long-acting forms
- Sigalos JT, Pastuszak AW, Sexual Medicine Reviews, 2018: Rationale for combining GHRH analogues with ghrelin-receptor agonists (like ipamorelin) to amplify GH pulsatility